Ongoing Clinical Trials for Ear Discomfort
This article provides information about ongoing clinical trials for ear discomfort, specifically focusing on conditions affecting the inner ear that can cause dizziness and related symptoms. Currently, there is 1 clinical trial investigating treatments for conditions associated with ear discomfort, including vertigo and balance disorders.
Clinical trial locations
Study on Meniere’s Disease: Comparing Methylprednisolone and Placebo for Patients with Unilateral Meniere’s Disease
This clinical trial is being conducted in the Netherlands and focuses on treating Menière’s disease, a disorder of the inner ear that can cause significant ear discomfort along with dizzy spells, hearing loss, and ringing in the ears. The condition affects the inner ear and leads to episodes of vertigo, which is an intense sensation of spinning or dizziness that can be very disabling for patients.
Main focus and goal: The trial aims to determine whether injections of methylprednisolone, a corticosteroid medication, are more effective than placebo in reducing the frequency of vertigo attacks in patients with Menière’s disease. The medication is delivered directly into the ear through a method called intratympanic injection, which allows it to target the affected area more precisely. The study will follow participants for one year to assess how well the treatment controls vertigo attacks compared to not receiving the active medication. Researchers will also monitor participants’ quality of life, including how dizziness and tinnitus affect their daily activities.
Investigational drug: The main medication being tested is methylprednisolone, administered at a dose of 62.5 mg/ml through injections into the ear. Methylprednisolone is a corticosteroid that works by reducing inflammation and suppressing immune system activity in the inner ear. By targeting inflammation, the medication may help decrease the frequency of vertigo episodes. The study will also consider the use of other medications administered through ear injections, including dexamethasone, triamcinolone, and gentamicin, to assess their impact on hearing and overall well-being. Additionally, metoclopramide may be used to help manage nausea and vomiting, which are common symptoms during vertigo attacks.
Who can participate – inclusion criteria:
- Adults over 18 years of age
- Diagnosed with unilateral Menière’s disease, meaning the condition affects only one ear
- Must have experienced at least 4 vertigo attacks in the last 6 months
- Both males and females are eligible to participate
Who cannot participate – exclusion criteria:
- Patients without a diagnosis of unilateral Menière’s disease
- Those currently participating in another clinical trial
- Patients with allergies or adverse reactions to the study medication
- Individuals with other medical conditions that might interfere with the study
- Patients who have had recent surgery or medical procedures that might affect the study results
- Those unable to follow study procedures or attend follow-up visits
- Vulnerable populations, including those unable to give informed consent
What to expect during the trial: Upon joining, you will be informed about the study’s purpose and asked to provide consent. An initial assessment will confirm your eligibility through a review of your medical history and physical examination. During the treatment phase, you will receive intratympanic injections at specified intervals according to the study protocol. Throughout the trial, your health and response to treatment will be closely monitored through regular check-ups, and you may be asked to complete questionnaires about your symptoms and quality of life. At the end of the trial, a final assessment will evaluate the treatment’s effectiveness, and you will be informed about the results.
Summary
Currently, there is one ongoing clinical trial focused on treating conditions associated with ear discomfort, specifically Menière’s disease. This trial is taking place in the Netherlands and is investigating whether corticosteroid injections delivered directly into the ear can help reduce the frequency of vertigo attacks. The study represents an important effort to find more effective treatments for patients suffering from this debilitating inner ear condition that causes dizziness, hearing loss, and significant impact on quality of life. The trial uses a carefully controlled approach, comparing the active medication with placebo to determine true effectiveness over a one-year period.